These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32770176)

  • 1. Acquired ATRX Loss and ALT Phenotype Through Tumor Recurrences in a Case of Pleomorphic Xanthoastrocytoma Suggest Their Possible Roles in Tumor Progression.
    Dal Col P; Poncet D; Rivoirard R; Vassal F; Bernichon E; Boutet C; Péoc'h M; Forest F
    J Neuropathol Exp Neurol; 2020 Sep; 79(9):1011-1014. PubMed ID: 32770176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia.
    Rodriguez FJ; Brosnan-Cashman JA; Allen SJ; Vizcaino MA; Giannini C; Camelo-Piragua S; Webb M; Matsushita M; Wadhwani N; Tabbarah A; Hamideh D; Jiang L; Chen L; Arvanitis LD; Alnajar HH; Barber JR; Rodríguez-Velasco A; Orr B; Heaphy CM
    Brain Pathol; 2019 Jan; 29(1):126-140. PubMed ID: 30192422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
    Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
    J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The genetic landscape of anaplastic pleomorphic xanthoastrocytoma.
    Phillips JJ; Gong H; Chen K; Joseph NM; van Ziffle J; Bastian BC; Grenert JP; Kline CN; Mueller S; Banerjee A; Nicolaides T; Gupta N; Berger MS; Lee HS; Pekmezci M; Tihan T; Bollen AW; Perry A; Shieh JTC; Solomon DA
    Brain Pathol; 2019 Jan; 29(1):85-96. PubMed ID: 30051528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics of circumscribed high-grade astrocytomas with an unusual combination of BRAF V600E, ATRX, and CDKN2A/B alternations.
    Murakami C; Yoshida Y; Yamazaki T; Yamazaki A; Nakata S; Hokama Y; Ishiuchi S; Akimoto J; Shishido-Hara Y; Yoshimoto Y; Matsumura N; Nobusawa S; Ikota H; Yokoo H
    Brain Tumor Pathol; 2019 Jul; 36(3):103-111. PubMed ID: 30972500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological and genetic association between epithelioid glioblastoma and pleomorphic xanthoastrocytoma.
    Furuta T; Miyoshi H; Komaki S; Arakawa F; Morioka M; Ohshima K; Nakada M; Sugita Y
    Neuropathology; 2018 Jun; 38(3):218-227. PubMed ID: 29532523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it?
    Vaubel R; Zschernack V; Tran QT; Jenkins S; Caron A; Milosevic D; Smadbeck J; Vasmatzis G; Kandels D; Gnekow A; Kramm C; Jenkins R; Kipp BR; Rodriguez FJ; Orr BA; Pietsch T; Giannini C
    Brain Pathol; 2021 Jan; 31(1):20-32. PubMed ID: 32619305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.
    Grandin N; Pereira B; Cohen C; Billard P; Dehais C; Carpentier C; Idbaih A; Bielle F; Ducray F; Figarella-Branger D; Delattre JY; Sanson M; Lomonte P; Poncet D; Verrelle P; Charbonneau M;
    Acta Neuropathol Commun; 2019 Nov; 7(1):175. PubMed ID: 31706351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A case of high-grade astrocytoma with BRAF and ATRX mutations following a long-standing course over two decades.
    Nakata S; Horiguchi K; Ishiuchi S; Yoshimoto Y; Yamada S; Nobusawa S; Ikota H; Hirato J; Yokoo H
    Neuropathology; 2017 Aug; 37(4):351-357. PubMed ID: 28185325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined "Infiltrating Astrocytoma/Pleomorphic Xanthoastrocytoma" Harboring IDH1 R132H and BRAF V600E Mutations.
    Yamada S; Kipp BR; Voss JS; Giannini C; Raghunathan A
    Am J Surg Pathol; 2016 Feb; 40(2):279-84. PubMed ID: 26414224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative lengthening of telomeres in molecular subgroups of paediatric high-grade glioma.
    Minasi S; Baldi C; Gianno F; Antonelli M; Buccoliero AM; Pietsch T; Massimino M; Buttarelli FR
    Childs Nerv Syst; 2021 Mar; 37(3):809-818. PubMed ID: 33128602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant transformation of pleomorphic xanthoastrocytoma and differential diagnosis: case report.
    Watanabe N; Ishikawa E; Kohzuki H; Sakamoto N; Zaboronok A; Matsuda M; Shibuya M; Matsumura A
    BMC Neurol; 2020 Jan; 20(1):21. PubMed ID: 31941461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma.
    Hosono J; Nitta M; Masui K; Maruyama T; Komori T; Yokoo H; Saito T; Muragaki Y; Kawamata T
    World Neurosurg; 2019 Jun; 126():624-630. PubMed ID: 30599247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation.
    Vaubel RA; Caron AA; Yamada S; Decker PA; Eckel Passow JE; Rodriguez FJ; Nageswara Rao AA; Lachance D; Parney I; Jenkins R; Giannini C
    Brain Pathol; 2018 Mar; 28(2):172-182. PubMed ID: 28181325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma.
    Tabouret E; Bequet C; Denicolaï E; Barrié M; Nanni I; Metellus P; Dufour H; Chinot O; Figarella-Branger D
    Eur J Surg Oncol; 2015 Dec; 41(12):1685-90. PubMed ID: 26454767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative lengthening of telomeres (ALT) in pediatric high-grade gliomas can occur without ATRX mutation and is enriched in patients with pathogenic germline mismatch repair (MMR) variants.
    Stundon JL; Ijaz H; Gaonkar KS; Kaufman RS; Jin R; Karras A; Vaksman Z; Kim J; Corbett RJ; Lueder MR; Miller DP; Guo Y; Santi M; Li M; Lopez G; Storm PB; Resnick AC; Waanders AJ; MacFarland SP; Stewart DR; Diskin SJ; Rokita JL; Cole KA
    Neuro Oncol; 2023 Jul; 25(7):1331-1342. PubMed ID: 36541551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMARCAL1 loss and alternative lengthening of telomeres (ALT) are enriched in giant cell glioblastoma.
    Brosnan-Cashman JA; Davis CM; Diplas BH; Meeker AK; Rodriguez FJ; Heaphy CM
    Mod Pathol; 2021 Oct; 34(10):1810-1819. PubMed ID: 34103668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alternative lengthening of telomere phenotype is significantly associated with loss of ATRX expression in high-grade pediatric and adult astrocytomas: a multi-institutional study of 214 astrocytomas.
    Abedalthagafi M; Phillips JJ; Kim GE; Mueller S; Haas-Kogen DA; Marshall RE; Croul SE; Santi MR; Cheng J; Zhou S; Sullivan LM; Martinez-Lage M; Judkins AR; Perry A
    Mod Pathol; 2013 Nov; 26(11):1425-32. PubMed ID: 23765250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.